
Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action date of May 14, 2021 Top-line results from the Phase 3 PRINCE study in treatment …